4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model
Preprint
Abstract
4-Methylumbelliferone (4-MU) inhibits hyaluronic acid (HA) synthesis and is currently approved in Europe for biliary spasm. 4-MU administration reduces perineuronal nets (PNNs), and enzymatic degradation of PNNs in mouse models of Alzheimer’s disease (AD) attenuates memory impairment. Although 4-MU has therapeutic efficacy in rodent models of fibrosis and cancer, it has not been examined in an Alzheimer’s model. Here, we evaluated the impact of long-term 4-MU treatment in the APP/PS1 amyloid mouse model. From three months of age, mice were on either a vehicle or 4-MU–supplemented diet for 70 days or 52 weeks. Short and long-term 4-MU treatment decreased the soluble parenchymal Aβ 1-42 /Aβ 1-40 ratio. Reductions in insoluble amyloid plaque were observed following 52 weeks of treatment. Extended 4-MU administration also reduced PNN intensity and ameliorated spatial memory deficits in APP/PS1 mice. These findings provide support for targeting brain extracellular matrix (ECM) as a therapeutic strategy for AD.Keywords
This publication has 67 references indexed in Scilit:
- Inhibitor of hyaluronic acid synthesis 4-methylumbelliferone (4-MU) as a potential anti-inflammatory substance in acute neuroinflammation model in vivoInflammopharmacology, 2025
- Aggrecan protects against plaque accumulation and is essential for proper microglial responses to plaquesCell Reports, 2025
- Extracellular Matrix Remodeling Alleviates Memory Deficits in Alzheimer's Disease by Enhancing the Astrocytic Autophagy‐Lysosome PathwayAdvanced Science, 2024
- A comprehensive atlas of perineuronal net distribution and colocalization with parvalbumin in the adult mouse brainCell Reports, 2023
- Oral treatment of 4-methylumbelliferone reduced perineuronal nets and improved recognition memory in miceBrain Research Bulletin, 2022
- Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brainAlzheimer's & Dementia, 2021
- Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's diseaseBehavioural Brain Research, 2011
- Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40Human Mutation, 2006
- Bral1, a Brain-Specific Link Protein, Colocalizing with the Versican V2 Isoform at the Nodes of Ranvier in Developing and Adult Mouse Central Nervous SystemsMolecular and Cellular Neuroscience, 2002
- Distribution of Aβ-associated proteins in cerebrovascular amyloid of Alzheimer's diseaseActa Neuropathologica, 1998